Osteoporosis Management in the Era of COVID-19

Elaine W. Yu, Elena Tsourdi, Bart L. Clarke, Douglas C. Bauer, Matthew T. Drake

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available.

Original languageEnglish (US)
Pages (from-to)1009-1013
Number of pages5
JournalJournal of Bone and Mineral Research
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2020

Keywords

  • ABALOPARATIDE
  • BISPHOSPHONAT
  • COVID-19
  • DENOSUMAB
  • FRACTURES
  • OSTEOPOROSIS
  • ROMOSOZUMAB
  • TERIPARATIDE

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Osteoporosis Management in the Era of COVID-19'. Together they form a unique fingerprint.

  • Cite this